Bionor Pharma ASA (BIONOR) - Financial and Strategic SWOT Analysis Review

Date: May 26, 2015
Pages: 44
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: BC26C164A61EN
Leaflet:

Download PDF Leaflet

Bionor Pharma ASA (BIONOR) - Financial and Strategic SWOT Analysis Review
Bionor Pharma ASA (BIONOR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Bionor Pharma ASA (Bionor Pharma), formerly Nutri Pharma ASA, is a peptide vaccine company, which develops vaccines for viral diseases. It holds expertise in the development of vaccines for HIV and other deadly viruses. Bionor Pharma by utilizing its proprietary technology platform develops modified peptide based vaccines targeting rapidly mutating viruses. Its pipeline product portfolio includes four different vaccine candidates, namely, Vacc-4x, Vacc-C5, Vacc-HIV (combination of Vacc-4x and Vacc-C5) and Vacc-Flu. The company also manages a portfolio of nutritional and weight management supplements. It is formed as business combination between vaccine developer Bionor Immuno AS and the nutraceutical company Nutri Pharma ASA. Bionor Pharma is headquartered at Oslo, Norway.

Bionor Pharma ASA Key Recent Developments

May 13, 2015: Bionor appoints new Chairman and three Non-Executive Directors
May 13, 2015: Bionor Pharma - First Quarter 2015 results
May 12, 2015: Bionor appoints Vice President for Investor Relations and Communications
May 06, 2015: Bionor appoints new Chief Financial Officer
Mar 27, 2015: Bionor announces additions to the executive management team and interim CFO

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company. - The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably. - Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance. - Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research. - Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.Note: Some sections may be missing if data is unavailable for the company
SECTION 1 - ABOUT THE COMPANY

Bionor Pharma ASA - Key Facts
Bionor Pharma ASA - Key Employees
Bionor Pharma ASA - Key Employee Biographies
Bionor Pharma ASA - Major Products and Services
Bionor Pharma ASA - Pharmaceutical Pipeline Products Data
Bionor Pharma ASA, Pipeline Products by Therapy Area
Bionor Pharma ASA, Pipeline Products by Development Phase
Bionor Pharma ASA - History
Bionor Pharma ASA - Company Statement
Bionor Pharma ASA - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Bionor Pharma ASA - Business Description
Bionor Pharma ASA - Corporate Strategy
Bionor Pharma ASA - SWOT Analysis
SWOT Analysis - Overview
Bionor Pharma ASA - Strengths
Strength - Lead Product: Vacc-4x
Strength - Proprietary Technology Platform
Strength - Strong R&D Activities
Bionor Pharma ASA - Weaknesses
Weakness - History of Operating Losses
Weakness - Working Capital Concerns
Bionor Pharma ASA - Opportunities
Opportunity - Changing Demographics
Opportunity - Market Potential: HIV
Opportunity - Partnerships and Collaborations
Bionor Pharma ASA - Threats
Threat - Intense Competition
Threat - Stringent Government Regulations
Threat - Uncertain R&D Outcomes
Bionor Pharma ASA - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Bionor Pharma ASA, Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015
Bionor Pharma ASA, Pharmaceuticals & Healthcare, Deals By Type, 2009 to YTD 2015
Bionor Pharma ASA, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

May 13, 2015: Bionor appoints new Chairman and three Non-Executive Directors
May 13, 2015: Bionor Pharma - First Quarter 2015 results
May 12, 2015: Bionor appoints Vice President for Investor Relations and Communications
May 06, 2015: Bionor appoints new Chief Financial Officer
Mar 27, 2015: Bionor announces additions to the executive management team and interim CFO
Feb 25, 2015: Bionor Pharma - Fourth Quarter 2014 results
Jan 09, 2015: David Horn Solomon assumes the role as President and Chief Executive Officer of Bionor Pharma
Jan 02, 2015: Bionor Pharma: Synne H. Roine resigns as CFO
Nov 04, 2014: Bionor Pharma Announces Third Quarter Results 2014
Aug 15, 2014: Bionor Pharma Announces Second Quarter Results 2014

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES
Bionor Pharma ASA, Key Facts
Bionor Pharma ASA, Key Employees
Bionor Pharma ASA, Key Employee Biographies
Bionor Pharma ASA, Major Products and Services
Bionor Pharma ASA, Number of Pipeline Products by Therapy Area
Bionor Pharma ASA, Number of Pipeline Products by Development Stage
Bionor Pharma ASA, Pipeline Products By Therapy Area and Development Phase
Bionor Pharma ASA, History
Bionor Pharma ASA, Other Locations
Bionor Pharma ASA, Subsidiaries
Bionor Pharma ASA, Key Competitors
Bionor Pharma ASA, Ratios based on current share price
Bionor Pharma ASA, Annual Ratios
Bionor Pharma ASA, Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015
Bionor Pharma ASA, Pharmaceuticals & Healthcare, Deals By Type, 2009 to YTD 2015
Bionor Pharma ASA, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES
Bionor Pharma ASA, Pipeline Products by Therapy Area
Bionor Pharma ASA, Pipeline Products by Development Phase
Bionor Pharma ASA, Performance Chart (2010 - 2014)
Bionor Pharma ASA, Ratio Charts
Bionor Pharma ASA, Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015
Bionor Pharma ASA, Pharmaceuticals & Healthcare, Deals by Type, 2009 to YTD 2015
Skip to top


Ask Your Question

Bionor Pharma ASA (BIONOR) - Financial and Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: